Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors
This study highlights several significant associations between the occurrence of endocrine irAEs and oncological parameters (renal/adrenal metastases, TNM stage), therapeutic factors (use of TKIs), and laboratory markers (neutrophil percentage) in RCC patients. These predictors may be useful in identifying patients who are more likely to develop endocrine irAEs and therefore require more rigorous endocrine surveillance during treatment.
Authors
- Angelo Cignarelli (ORCID: https://orcid.org/0000-0001-6477-9031)
- Camillo Porta (ORCID: https://orcid.org/0000-0003-2412-1563)
- Carlo Ganini (ORCID: https://orcid.org/0000-0002-5839-3965)
- A. Borraccino
- Luigi Laviola (ORCID: https://orcid.org/0000-0001-8860-5845)
- Mariangela Caporusso (ORCID: https://orcid.org/0009-0008-7331-3936)
- Francesco Giorgino (ORCID: https://orcid.org/0000-0001-7372-2678)
- Nicola Marrano (ORCID: https://orcid.org/0000-0001-6587-6087)
- Sebastio Perrini (ORCID: https://orcid.org/0000-0002-2728-7721)
- Annalisa Natalicchio
Institutions
- LUM Jean Monnet University (IT)
- Ospedale Generale Regionale Francesco Miulli (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Journal of Endocrinological Investigation
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1007/s40618-025-02732-z
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04